Alexia Iasonos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7406468/publications.pdf

Version: 2024-02-01

156 papers	9,225 citations	57681 46 h-index	51423 90 g-index
159 all docs	159 docs citations	159 times ranked	12845 citing authors

#	Article	IF	Citations
1	Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecologic Oncology, 2022, 164, 12-17.	0.6	6
2	Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas. Gynecologic Oncology Reports, 2022, 40, 100980.	0.3	0
3	Stopping rules for phase I clinical trials with dose expansion cohorts. Statistical Methods in Medical Research, 2022, 31, 334-347.	0.7	2
4	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecologic Oncology, 2021, 160, 51-55.	0.6	2
5	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. Gynecologic Oncology, 2021, 160, 438-444.	0.6	9
6	Finding Optimism in Clinical Trials: A Numbers Perspective. Oncologist, 2021, 26, 84-85.	1.9	1
7	The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecologic Oncology, 2021, 160, 99-105.	0.6	10
8	A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers. Gynecologic Oncology, 2021, 160, 71-76.	0.6	9
9	Prophylactic Negative Pressure Wound Therapy After Laparotomy for Gynecologic Surgery. Obstetrics and Gynecology, 2021, 137, 334-341.	1.2	12
10	Phase I Clinical Trials in Adoptive T-Cell Therapies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 815-834.	0.5	4
11	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. Gynecologic Oncology, 2021, 160, 696-703.	0.6	2
12	Effect of a Predictive Model on Planned Surgical Duration Accuracy, Patient Wait Time, and Use of Presurgical Resources. JAMA Surgery, 2021, 156, 315.	2.2	37
13	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. Gynecologic Oncology, 2021, 161, 521-526.	0.6	2
14	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3867-3875.	3.2	15
15	Bevacizumab in advanced endometrial cancer. Gynecologic Oncology, 2021, 161, 720-726.	0.6	11
16	Randomised Phase 1 clinical trials in oncology. British Journal of Cancer, 2021, 125, 920-926.	2.9	15
17	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	0.6	11
18	Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment. Journal of Surgical Oncology, 2021, 124, 846-851.	0.8	0

#	Article	IF	Citations
19	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	0.8	66
20	Non-exenterative surgical management of recurrent endometrial carcinoma. Gynecologic Oncology, 2021, 162, 268-276.	0.6	5
21	Non-exenterative surgical management of recurrent endometrial carcinoma: patient characteristics and outcomes. Gynecologic Oncology, 2021, 162, S212.	0.6	0
22	Provider perception of racial healthcare disparities among women with gynecologic malignancies. Gynecologic Oncology, 2021, 162, S51-S52.	0.6	1
23	Listening to our peers so we can listen to our patients: a survey of racism experienced by gynecologic oncologists. Gynecologic Oncology, 2021, 162, S14-S15.	0.6	0
24	Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer. , 2021, 9, e002752.		2
25	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecologic Oncology, 2021, 163, 294-298.	0.6	9
26	Commentary on Price and Scott: Complex innovative trial design. Clinical Trials, 2021, 18, 174077452110506.	0.7	0
27	Controlled backfill in oncology dose-finding trials. Contemporary Clinical Trials, 2021, 111, 106605.	0.8	11
28	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. International Journal of Gynecological Cancer, 2021, 31, 222-231.	1.2	2
29	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. JCSM Clinical Reports, 2021, 6, 11-16.	0.5	0
30	The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer. JCSM Clinical Reports, 2021, 6, 11-16.	0.5	3
31	Coherence principles in intervalâ€based dose finding. Pharmaceutical Statistics, 2020, 19, 137-144.	0.7	3
32	Positron Lymphography via Intracervical ¹⁸F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. Journal of Nuclear Medicine, 2020, 61, 1123-1130.	2.8	8
33	Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer, 2020, 126, 1274-1282.	2.0	37
34	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecologic Oncology, 2020, 156, 147-153.	0.6	61
35	Ethical and Policy Issues for Seamless Phase I Oncology Trials. Journal of Clinical Oncology, 2020, 38, 669-673.	0.8	11
36	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research, 2020, 26, 1624-1632.	3.2	103

#	Article	IF	Citations
37	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecologic Oncology, 2020, 159, 66-71.	0.6	12
38	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. International Journal of Gynecological Cancer, 2020, 30, 1915-1921.	1.2	29
39	Surveillance patterns of cervical cancer patients treated with conization alone. International Journal of Gynecological Cancer, 2020, 30, 1129-1135.	1.2	3
40	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. Gynecologic Oncology, 2020, 158, 397-401.	0.6	7
41	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecologic Oncology, 2020, 157, 214-221.	0.6	2
42	Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry. Cancer Discovery, 2020, 10, 526-535.	7.7	36
43	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 1554-1561.	1.2	7
44	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. Journal of Gynecologic Oncology, 2020, 31, e17.	1.0	22
45	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. International Journal of Gynecological Cancer, 2020, 30, 1183-1188.	1.2	4
46	A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen. International Journal of Gynecological Cancer, 2019, 29, 904-909.	1.2	5
47	Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecologic Oncology, 2019, 155, 51-57.	0.6	14
48	Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature, 2019, 567, 521-524.	13.7	222
49	Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program. JAMA Oncology, 2019, 5, 570.	3.4	9
50	Variance prior specification for a basket trial design using Bayesian hierarchical modeling. Clinical Trials, 2019, 16, 142-153.	0.7	25
51	Adjuvant chemotherapy in patients with operable granulosa cell tumors of the ovary: a surveillance, epidemiology, and end results cohort study. Cancer Medicine, 2018, 7, 2280-2287.	1.3	21
52	Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. Annals of Surgical Oncology, 2018, 25, 984-990.	0.7	12
53	Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. Gynecologic Oncology, 2018, 149, 43-48.	0.6	10
54	Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecologic Oncology, 2018, 151, 287-293.	0.6	23

#	Article	IF	Citations
55	A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer. International Journal of Gynecological Cancer, 2018, 28, 1176-1182.	1.2	5
56	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. Gynecologic Oncology, 2018, 151, 24-31.	0.6	64
57	Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kÎ´ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies. Blood, 2018, 132, 2893-2893.	0.6	13
58	Sequential monitoring of Phase I dose expansion cohorts. Statistics in Medicine, 2017, 36, 204-214.	0.8	12
59	An efficient basket trial design. Statistics in Medicine, 2017, 36, 1568-1579.	0.8	82
60	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. Gynecologic Oncology, 2017, 145, 230-235.	0.6	43
61	Survival of Patients with Serous Uterine Carcinoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2017, 24, 1965-1971.	0.7	47
62	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecologic Oncology, 2017, 145, 27-31.	0.6	95
63	A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups. Data in Brief, 2017, 12, 667-675.	0.5	12
64	Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. Contemporary Clinical Trials, 2017, 63, 40-50.	0.8	10
65	A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs, 2017, 35, 742-750.	1.2	10
66	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. Gynecologic Oncology, 2017, 147, 115-119.	0.6	31
67	Phase I Designs That Allow for Uncertainty in the Attribution of Adverse Events. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 1015-1030.	0.5	4
68	Practical Implementation: Protocol Development. , 2017, , 163-186.		0
69	Specifying the True- and False-Positive Rates in Basket Trials. JCO Precision Oncology, 2017, 1, 1-5.	1.5	7
70	Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. Journal of Clinical Oncology, 2017, 35, 271-273.	0.8	110
71	Time to publication of oncology trials and why some trials are never published. PLoS ONE, 2017, 12, e0184025.	1.1	19
72	Picking the Right Patient for Human Epidermal Growth Factor Receptor 3â€“Targeted Therapy in Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2016, 34, 4312-4314.	0.8	1

#	Article	IF	Citations
73	A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission. Cancers, 2016, 8, 46.	1.7	33
74	Dimension of model parameter space and operating characteristics in adaptive doseâ€finding studies. Statistics in Medicine, 2016, 35, 3760-3775.	0.8	23
75	Reply to M.P. Decatris et al. Journal of Clinical Oncology, 2016, 34, 887-887.	0.8	1
76	Beyond the doseâ€limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Cancer, 2016, 122, 1228-1237.	2.0	10
77	Dose Expansion Cohorts in Phase I Trials. Statistics in Biopharmaceutical Research, 2016, 8, 161-170.	0.6	33
78	Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker. Clinical Cancer Research, 2016, 22, 2114-2120.	3.2	6
79	Measuring Toxicity in Phase I Clinical Trialsâ€”Letter. Clinical Cancer Research, 2016, 22, 1828-1828.	3.2	0
80	Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemporary Clinical Trials, 2016, 50, 124-134.	0.8	13
81	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. Gynecologic Oncology, 2016, 143, 496-503.	0.6	12
82	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecologic Oncology, 2016, 140, 436-442.	0.6	97
83	Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical Cancer Research, 2016, 22, 553-559.	3.2	16
84	Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping. Annals of Surgical Oncology, 2016, 23, 196-202.	0.7	86
85	Geriatric Assessment as a Predictor of Delirium and Other Outcomes in Elderly Patients With Cancer. Annals of Surgery, 2015, 261, 1085-1090.	2.1	74
86	Prognostic and Predictive Values and Statistical Interactions in the Era of Targeted Treatment. Genetic Epidemiology, 2015, 39, 509-517.	0.6	8
87	Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21Âdays or q28Âdays) for patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 747-755.	1.1	21
88	Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?. Journal of Clinical Oncology, 2015, 33, 2221-2225.	0.8	35
89	The role of systemic chemotherapy in the management of granulosa cell tumors. Gynecologic Oncology, 2015, 136, 505-511.	0.6	45
90	Ovarian clear cell carcinoma, outcomes by stage: The MSK experience. Gynecologic Oncology, 2015, 139, 236-241.	0.6	70

#	Article	IF	Citations
91	Early phase clinical trialsâ€"are dose expansion cohorts needed?. Nature Reviews Clinical Oncology, 2015, 12, 626-628.	12.5	34
92	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. Oncotarget, 2015, 6, 19316-19327.	0.8	13
93	Bridging Solutions in Dose-Finding Problems. Statistics in Biopharmaceutical Research, 2014, 6, 185-197.	0.6	31
94	Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials. Journal of Clinical Oncology, 2014, 32, 2505-2511.	0.8	93
95	Reply to M. Voskoboynik et al. Journal of Clinical Oncology, 2014, 32, 3199-3200.	0.8	1
96	Nomogram to Predict Cycle-One Serious Drug-Related Toxicity in Phase I Oncology Trials. Journal of Clinical Oncology, 2014, 32, 519-526.	0.8	47
97	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology, 2014, 134, 455-461.	0.6	180
98	Classification and regression tree (CART) analysis of endometrial carcinoma: Seeing the forest for the trees. Gynecologic Oncology, 2013, 130, 452-456.	0.6	87
99	BRAF Mutation is associated with early stage disease and improved outcome in patients with lowâ€grade serous ovarian cancer. Cancer, 2013, 119, 548-554.	2.0	169
100	Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy. Journal of the National Cancer Institute, 2013, 105, 499-503.	3.0	79
101	Design Considerations for Dose-Expansion Cohorts in Phase I Trials. Journal of Clinical Oncology, 2013, 31, 4014-4021.	0.8	49
102	Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2013, 31, 724-730.	0.8	91
103	External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. Cancer, 2013, 119, 1816-1822.	2.0	54
104	The Impact of Nonâ€"Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials. Clinical Cancer Research, 2012, 18, 5179-5187.	3.2	19
105	Identifying Clinical Improvement in Consolidation Single-Arm Phase 2 Trials in Patients With Ovarian Cancer in Second or Greater Clinical Remission. International Journal of Gynecological Cancer, 2012, 22, 63-69.	1.2	2
106	Dose-Finding Designs Based on the Continual Reassessment Method. , 2012, , 21-52.		1
107	Interplay of priors and skeletons in twoâ€stage continual reassessment method. Statistics in Medicine, 2012, 31, 4321-4336.	0.8	13
108	Eribulin mesylate (halichondrin B analog E7389) in platinumâ€resistant and platinumâ€sensitive ovarian cancer. Cancer, 2012, 118, 2403-2410.	2.0	18

#	Article	IF	Citations
109	Improved survival for BRCA2â€associated serous ovarian cancer compared with both BRCAâ€negative and BRCA1â€associated serous ovarian cancer. Cancer, 2012, 118, 3703-3709.	2.0	72
110	External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecologic Oncology, 2012, 125, 526-530.	0.6	19
111	Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer. Gynecologic Oncology, 2012, 126, 58-63.	0.6	17
112	A nomogram to predict postresection 5â€year overall survival for patients with uterine leiomyosarcoma. Cancer, 2012, 118, 660-669.	2.0	126
113	Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology, 2011, 123, 196-199.	0.6	10
114	Estimating the doseâ€“toxicity curve in completed phase I studies. Statistics in Medicine, 2011, 30, 2117-2129.	0.8	13
115	Continual reassessment and related designs in doseâ€finding studies. Statistics in Medicine, 2011, 30, 2057-2061.	0.8	13
116	Incorporating lower grade toxicity information into dose finding designs. Clinical Trials, 2011, 8, 370-379.	0.7	31
117	Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Nonâ€“Hodgkin Lymphoma. Clinical Cancer Research, 2011, 17, 2493-2501.	3.2	27
118	Consolidation strategies in ovarian cancer: Observations for future clinical trials. Gynecologic Oncology, 2010, 116, 66-71.	0.6	14
119	Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic Oncology, 2010, 116, 424-429.	0.6	92
120	The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecologic Oncology, 2010, 116, 326-331.	0.6	43
121	The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. Gynecologic Oncology, 2010, 116, 351-357.	0.6	61
122	A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecologic Oncology, 2010, 117, 317-323.	0.6	66
123	A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer. Gynecologic Oncology, 2010, 119, 358-365.	0.6	108
124	Patterns of recurrence and role of adjuvant chemotherapy in stage IIâ€“IV serous ovarian borderline tumors. Gynecologic Oncology, 2010, 119, 270-273.	0.6	34
125	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2010, 28, 1896-1903.	0.8	293
126	Epithelial Membrane Protein-2 Is a Novel Therapeutic Target in Ovarian Cancer. Clinical Cancer Research, 2010, 16, 3954-3963.	3.2	29

#	Article	IF	Citations
127	Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems. Journal of Clinical Oncology, 2009, 27, 2066-2072.	0.8	119
128	Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecologic Oncology, 2009, 115, 209-214.	0.6	27
129	Sequential adjuvant chemotherapy after surgical resection of highâ€risk urothelial carcinoma. Cancer, 2009, 115, 5193-5201.	2.0	13
130	Endometrial Carcinomas in Women Aged 40 Years and Younger: Tumors Associated With Loss of DNA Mismatch Repair Proteins Comprise a Distinct Clinicopathologic Subset. American Journal of Surgical Pathology, 2009, 33, 1869-1877.	2.1	110
131	The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecologic Oncology, 2008, 108, 287-292.	0.6	109
132	Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: An updated series. Gynecologic Oncology, 2008, 108, 482-485.	0.6	76
133	Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. Gynecologic Oncology, 2008, 109, 39-42.	0.6	20
134	A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage Iâ€“IV uterine carcinosarcoma. Gynecologic Oncology, 2008, 111, 249-254.	0.6	68
135	Treatment patterns of FIGO Stage IB2 cervical cancer: A single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecologic Oncology, 2008, 111, 265-270.	0.6	36
136	How To Build and Interpret a Nomogram for Cancer Prognosis. Journal of Clinical Oncology, 2008, 26, 1364-1370.	0.8	2,273
137	Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission. Clinical Cancer Research, 2008, 14, 2740-2748.	3.2	98
138	A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clinical Trials, 2008, 5, 465-477.	0.7	143
139	Long-Term Toxicity Monitoring via Electronic Patient-Reported Outcomes in Patients Receiving Chemotherapy. Journal of Clinical Oncology, 2007, 25, 5374-5380.	0.8	173
140	Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer. Clinical Cancer Research, 2007, 13, 4170-4177.	3.2	127
141	Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract. Urology, 2007, 69, 255-259.	0.5	79
142	Predicting the Histology of Renal Masses Using Preoperative Doppler Ultrasonography. Journal of Urology, 2007, 177, 53-58.	0.2	44
143	A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer, 2007, 110, 2458-2466.	2.0	43
144	CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecologic Oncology, 2007, 104, 176-180.	0.6	60

#	Article	IF	Citations
145	Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecologic Oncology, 2007, 104, 435-442.	0.6	60
146	Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case series and review of the literature. Gynecologic Oncology, 2007, 105, 321-324.	0.6	158
147	Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials. Gynecologic Oncology, 2007, 106, 469-475.	0.6	34
148	Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer. Gynecologic Oncology, 2007, 107, 66-70.	0.6	23
149	Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities. Journal of the American Medical Informatics Association: JAMIA, 2007, 14, 264-268.	2.2	108
150	Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Investigational New Drugs, 2007, 25, 265-270.	1.2	124
151	Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncology, The, 2006, 7, 903-909.	5.1	512
152	The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: A 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecologic Oncology, 2006, 103, 714-718.	0.6	347
153	Lysophosphatidic acid acyltransferase-Î² (LPAAT-Î²) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. Cancer, 2006, 107, 1511-1519.	2.0	38
154	Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Clinical Cancer Research, 2006, 12, 5503-5510.	3.2	67
155	The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL).. Blood, 2005, 106, 2072-2072.	0.6	1
156	High Dose Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkinâ€™s Lymphoma.. Blood, 2005, 106, 2073-2073.	0.6	0